Under New CEO, GSK Will Leverage OTCs In Emerging Markets
This article was originally published in The Pink Sheet Daily
Glaxo will look at opportunities to expand its nonprescription business, as OTC and other products have more long-term sales consistency than Rx drugs, North American Pharmaceuticals President Viehbacher says.
You may also be interested in...
U.K. firm’s busy spring includes internal downsizing, external investments.
BioMedican is ready to produce CBG, cannabigerol, and THC-V, tetrahydrocannabivarin, through biosynthesis and plans by the end of the year to start making CBN, cannabinol, and THC-A, tetrahydrocannabinolic-acid.